The technology behind
The secret to finding high quality nanobodies lies in the in the strength of the libraries. Synobody has developed technology that allows creation of vastly diverse nanobody libraries quick and inexpensively. We call it Evolink technology.
On a robust foundation of libraries developed through Evolink technology we have build an advanced process of screening and validation. An optimized phage display pipeline allow for rapid screening and high throughput ELISA serve for solid validation.
Evolink
Anchored in Synobody’s core is the proprietary Evolink technology.
Evolink, is a pioneering approach to generating extensive and complex nanobody libraries with minimal resources. This approach facilitates the rapid and cost-effective identification of nanobodies.
Evolink employs four parental nanobody sequences, which are humanized to eliminate immunogenicity in downstream applications. These sequences serve as the foundation for all nanobody variants, and extensive mutagenesis is applied to the three hypervariable regions (CDRs) using site-directed mutagenesis.
Evolink is harnessing the power of site-directed mutagenesis while upholding precision and eliminating randomness, thereby ensuring high quality of each nanobody.
In house library
Readily available for screening and selection
In house library
We have developed a highly efficient and powerful in-house nanobody phage display library consisting of a vast collection (10^11) of nanobodies, and each nanobody is engineered for stability and high-affinity binding using our Evolink technology. The readily available nanobody library requires no processes and the screening thus commences immediately upon receiving the antigen.
​
Phage display
Upon receiving the target protein of your choice, we commence the screening process, which comprises of two to five rounds of phage display biopanning. The use of our optimized phage display pipeline facilitates the most rapid and reliable selection of functional nanobodies from our extensive library. Following the initial selection, we conduct small-scale production, which will subsequently undergo ELISA validation.
Elisa
Upon completion of the phage display biopanning rounds and small-scale production, we identify nanobody candidates with the highest binding affinities via ELISA. This methodological approach ensures the identification of nanobodies with exceptional binding characteristics and absence of production liabilities, thereby enabling the production of high-quality products tailored to your specific application.
After the completion of the ELISA validation process, the most promising nanobodies can be produced and delivered to you for further assessment in your applications. In the event that a significant quantity of the product is required, a larger scale production is available through special ordering. For additional information on this matter, please contact Synobody.
Sequencing
Once the validation is complete, we proceed to sequence the best nanobody candidates, taking great care to ensure their diversity and integrity. By employing these rigorous procedures, we provide you with nanobodies that meet the most stringent standards, ensuring optimal performance and reliability for your applications.
Production
Once the ideal nanobody candidates have been identified and validated, we possess the capability to produce them using our specialized production strain. Leveraging our advanced production techniques, we cultivate the strain under controlled conditions to achieve a substantial yield of the desired nanobodies. Our optimized production process ensures that the nanobodies are generated efficiently and in significant quantities, enabling you to access a robust supply for your specific applications.
We are here to help.
At Synobody, we have solutions that suits most needs, but we are aware that you might need specific information regarding your business in terms of choosing the right nanobodies. If you have any questions about which solution best matches you or your business’ needs, we are always ready to help.
